Search research articles
Contact Us
Filters
Showing results (201-210 of 215) with videos related to
Page
of 22
Sort By:
Blood
|
September 10, 1998
Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease
M André, M Henry-Amar, D Blaise, et al.
Leukemia & Lymphoma
|
April 1, 1997
Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte
C Gisselbrecht, C Haioun, E Lepage, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2005
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte
P Feugier, A Van Hoof, C Sebban, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 16, 2012
Diffuse large B-cell lymphoma of Waldeyer's ring has distinct clinicopathologic features: a GELA study
L de Leval, C Bonnet, C Copie-Bergman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 15, 2007
Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma
A Plonquet, C Haioun, J-P Jais, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 19, 2000
European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma
J M Foran, A Z Rohatiner, D Cunningham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 24, 1999
Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Société Francaise de Greffe de Moelle
M André, M Henry-Amar, J L Pico, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 21, 1998
CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma
J Lundin, A Osterborg, G Brittinger, et al.
Leukemia
|
July 11, 2008
The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab
J-P Jais, C Haioun, T J Molina, et al.
Bone Marrow Transplantation
|
September 15, 2015
Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study
E Van Den Neste, N Schmitz, N Mounier, et al.
Page
of 22
Search research articles
Search
Showing results (201-210 of 215) with videos related to
Sort By:
Page
of 22
Blood
|
September 10, 1998
Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease
M André, M Henry-Amar, D Blaise, et al.
Leukemia & Lymphoma
|
April 1, 1997
Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte
C Gisselbrecht, C Haioun, E Lepage, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2005
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte
P Feugier, A Van Hoof, C Sebban, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 16, 2012
Diffuse large B-cell lymphoma of Waldeyer's ring has distinct clinicopathologic features: a GELA study
L de Leval, C Bonnet, C Copie-Bergman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 15, 2007
Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma
A Plonquet, C Haioun, J-P Jais, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 19, 2000
European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma
J M Foran, A Z Rohatiner, D Cunningham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 24, 1999
Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Société Francaise de Greffe de Moelle
M André, M Henry-Amar, J L Pico, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 21, 1998
CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma
J Lundin, A Osterborg, G Brittinger, et al.
Leukemia
|
July 11, 2008
The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab
J-P Jais, C Haioun, T J Molina, et al.
Bone Marrow Transplantation
|
September 15, 2015
Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study
E Van Den Neste, N Schmitz, N Mounier, et al.
Page
of 22